Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Small Cell Lung Cancer, Combined Type”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00445848
What this trial is testing

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
SWOG Cancer Research Network 89
Testing effectiveness (Phase 2)Study completedNCT03728361
What this trial is testing

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Who this might be right for
Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine Carcinoma+9 more
Dwight Owen 55
Testing effectiveness (Phase 2)Study completedNCT02718066
What this trial is testing

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Who this might be right for
MelanomaRenal Cell CarcinomaNon-Small Cell Lung Cancer
HUYABIO International, LLC. 96
Large-scale testing (Phase 3)Ended earlyNCT02775006
What this trial is testing

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Who this might be right for
Carcinoma, Non-small Cell Lung
The Netherlands Cancer Institute 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03836352
What this trial is testing

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Who this might be right for
Ovarian CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more
ImmunoVaccine Technologies, Inc. (IMV Inc.) 184
Testing effectiveness (Phase 2)Ended earlyNCT05070247
What this trial is testing

TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Pancreatic CancerHepatocellular CancerMesothelioma+7 more
Takeda 61
Testing effectiveness (Phase 2)Looking for participantsNCT07718243
What this trial is testing

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

Who this might be right for
Melanoma (Skin Cancer)Non Small Cell Lung CancerSolid Tumor in Advanced Stage
Institute of Cancer Research, United Kingdom 62
Testing effectiveness (Phase 2)Ended earlyNCT05099549
What this trial is testing

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Who this might be right for
Squamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal Neoplasms+3 more
NKGen Biotech, Inc. 11
Early research (Phase 1)Ended earlyNCT02834247
What this trial is testing

TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Who this might be right for
Triple-Negative Breast NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Carcinoma, Squamous Cell+1 more
Calithera Biosciences, Inc 41
Early research (Phase 1)Study completedNCT01970540
What this trial is testing

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Who this might be right for
Endometrial AdenocarcinomasNeuroendocrine TumorsSmall-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
PharmaMar 122
Early research (Phase 1)Study completedNCT01131234
What this trial is testing

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Who this might be right for
Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic Oligodendroglioma+49 more
National Cancer Institute (NCI) 20
Early research (Phase 1)Ended earlyNCT00901537
What this trial is testing

Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer

Who this might be right for
Non-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
Loma Linda University 8
Testing effectiveness (Phase 2)WithdrawnNCT03361319
What this trial is testing

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

Who this might be right for
NSCLC, RecurrentAdenocarcinoma of Lung
Royal Marsden NHS Foundation Trust
Early research (Phase 1)Study completedNCT03758781
What this trial is testing

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Who this might be right for
Metastatic CancerRecurrent CancerSolid Tumor+6 more
H. Lee Moffitt Cancer Center and Research Institute 12
Early research (Phase 1)Study completedNCT00466232
What this trial is testing

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

Who this might be right for
Small Cell CarcinomaLung Cancer
HealthPartners Institute 16
Early research (Phase 1)UnknownNCT04137900
What this trial is testing

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Who this might be right for
Advanced Unresectable Solid TumorMetastatic Solid Tumor
TopAlliance Biosciences 499
Testing effectiveness (Phase 2)Study completedNCT03861793
What this trial is testing

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Who this might be right for
Advanced Solid Tumors
Mural Oncology, Inc 116
Testing effectiveness (Phase 2)Ended earlyNCT03277352
What this trial is testing

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Who this might be right for
Advanced MalignanciesMetastatic Cancer
Incyte Biosciences International Sàrl 10
Early research (Phase 1)Looking for participantsNCT06764771
What this trial is testing

BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Who this might be right for
Advanced Malignant Tumors
Bristol-Myers Squibb 437
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Next Page